É. Larousse and . Définitions,

D. Sur,

C. Hesson, Chapter 01 Power Points, vol.12

D. Sur,

É. Larousse and . Définitions, homéostasie -Dictionnaire de français Larousse

D. Sur,

L. Sherwood, Physiologie humaine

D. Sur, Energie et cellule eucaryote

D. Sur, page=tropo 11. ThingLink. Neuromuscular Junction by, 2018.

D. Sur, What makes Ca2+ ions bind to actin longer on slow muscle fibers than on fast muscle fibers? -Quora

D. Sur, Conversion de l'énergie chimique des plantes en énergie musculaire | Encyclopédie de l'Energie

V. Rodwell, D. Bender, K. Botham, P. Kennelly, A. Weil et al., Intradialytic creatine supplementation: A scientific rationale for improving the health and quality of life of dialysis patients -ScienceDirect, vol.15

D. Sur,

. Disponible, K. Busch, and H. Ninnemann, The controlling influence of ADP, ATP and magnesium on the activities of adenylate kinase, ATP synthase, ADP/ATP translocator and the mitochondrial respiration in plants, Plant Sci -PLANT SCI. 1 sept, vol.128, pp.85-95, 1997.

B. Alberts, A. Johnson, J. Lewis, and D. Morgan, Biologie moléculaire de la cellule

, Médecine Sciences Publications, 2017.

L. Castagné, Antenne Médicale de Prévention du Dopage (AMPD) du Languedoc Roussillon, 2013.

G. Carnac, Réparation et régénération du muscle squelettique adulte

S. Chargé and M. A. Rudnicki, Cellular and Molecular Regulation of Muscle Regeneration, Physiol Rev. janv, vol.84, issue.1, pp.209-247, 2004.

A. C. Scribd-;-mcpherron, A. M. Lawler, and S. J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature. 1 mai, vol.387, issue.6628, p.90, 1997.

L. Grobet, L. J. Martin, D. Poncelet, D. Pirottin, B. Brouwers et al., A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle, Nat Genet. sept, vol.17, issue.1, pp.71-75, 1997.

R. Kambadur, M. Sharma, T. Smith, and J. J. Bass, Mutations in myostatin, vol.8

, Double-Muscled Belgian Blue and Piedmontese Cattle, Genome Res, vol.9, 1997.

A. C. Mcpherron and S. Lee, Double muscling in cattle due to mutations in the myostatin gene, Proc Natl Acad Sci, vol.94, issue.23, p.61, 1997.

L. Grobet, D. Poncelet, L. J. Royo, B. Brouwers, D. Pirottin et al., Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle, Mamm Genome Off J Int Mamm Genome Soc. mars, vol.9, issue.3, p.210, 1998.

D. Sur, MSTN Gene -GeneCards | GDF8 Protein | GDF8 Antibody

. Disponible, N. F. Gonzalez-cadavid, W. E. Taylor, K. Yarasheski, I. Sinha-hikim et al., Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting, Proc Natl Acad Sci. 8 déc, vol.95, issue.25, pp.14938-14981, 1998.

S. B. Anderson, A. L. Goldberg, and M. Whitman, Identification of a Novel Pool of Extracellular Pro-myostatin in Skeletal Muscle, J Biol Chem. 14 mars, vol.283, issue.11, p.35, 2008.

Z. Huang, X. Chen, and D. Chen, Myostatin: A novel insight into its role in metabolism, signal pathways, and expression regulation, Cell Signal. sept, vol.23, issue.9, pp.1441-1447, 2011.

J. N. Cash, E. B. Angerman, C. Kattamuri, K. Nolan, H. Zhao et al., Structure of Myostatin·Follistatin-like 3, J Biol Chem. 6 janv, vol.287, issue.2, pp.1043-53, 2012.

C. Mcfarlane, G. Z. Hui, W. Amanda, H. Y. Lau, S. Lokireddy et al., Human myostatin negatively regulates human myoblast growth and differentiation

, Am J Physiol -Cell Physiol. juill, vol.301, issue.1, pp.195-203, 2011.

B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour et al.,

, Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression, Wikipedia [Internet, vol.277, pp.49831-49871, 2002.

R. Kumar and E. B. Thompson, The structure of the nuclear hormone receptors, Steroids. mai, vol.64, issue.5, pp.310-319, 1999.

C. Moussard and . Biologie-moléculaire, Biochimie des communications cellulaires

D. Boeck and S. , , vol.330, 2005.

P. Andrééva-gatéva, Récepteurs activables par les proliférateurs des peroxysomes (PPAR),: leur implication dans le métabolisme des hydrates de carbone et des lipides, Ann Biol Clin, vol.61, p.9, 2003.

N. Latruffe, Les peroxysomes et la prolifération cellulaire ou la prise en considération d'un organite méconnu. médecine/sciences, vol.8, p.239, 1992.

S. Tyagi, S. Sharma, P. Gupta, A. Saini, and C. Kaushal, The peroxisome proliferatoractivated receptor: A family of nuclear receptors role in various diseases, J Adv Pharm Technol Res, vol.2, issue.4, p.236, 2011.

C. Blanquart, (. Ppar?, and . Inflammatoire, Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system, Br J Pharmacol. mars, vol.129, issue.5, pp.823-857, 2000.

V. Zoete, A. Grosdidier, O. Michielin, K. K. Brown, B. R. Henke et al., A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat, Biochim Biophys Acta BBA -Mol Cell Biol Lipids. août, vol.1771, issue.8, pp.1415-1439, 1999.

P. Gervois, J. Fruchart, and . Ppar?, un récepteur nucléaire majeur de l'adipogenèse. médecine/sciences, janv, vol.19, issue.1, pp.20-22, 2003.

F. Laracine, Rôle des Peroxisome Proliferator-Activated Receptors (PPAR) dans le métabolisme lipidique, vol.106, 2009.

N. Wang, PPAR-? in Vascular Pathophysiology, PPAR Res, pp.1-10, 2008.

E. Ehrenborg and A. Krook, Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor, Pharmacol Rev. 1 sept, vol.61, issue.3, p.93, 2009.

M. Thevis and W. Schänzer, Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis -Potential implications for sports drug testing programs: Emerging drugs -Potential implications for sports drug testing, Rapid Commun Mass Spectrom. 15 mars, vol.30, issue.5, pp.635-51, 2016.

P. J. Fernandez-marcos and J. Auwerx, Regulation of PGC-1?, a nodal regulator of mitochondrial biogenesis, Am J Clin Nutr. 1 avr, vol.93, issue.4, pp.884-890, 2011.

V. A. Narkar, M. Downes, R. T. Yu, E. Embler, Y. Wang et al., AMPK and PPAR? Agonists Are Exercise Mimetics, Cell. août, vol.134, issue.3, pp.405-420, 2008.

A. Dopage and . Montpellier,

E. Woldt, Y. Sebti, L. A. Solt, C. Duhem, S. Lancel et al., Rev-erb-? modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy, Nat Med. août, vol.19, issue.8, pp.1039-1085, 2013.

D. A. Sinclair and L. Guarente, Small-Molecule Allosteric Activators of Sirtuins

B. J. North and D. A. Sinclair, Sirtuins: a conserved key unlocking AceCS activity, Annu Rev Pharmacol Toxicol. 6 janv, vol.54, issue.1, pp.363-80, 2014.

, *! Trends Biochem Sci. janv, 2007.

P. Bheda, H. Jing, C. Wolberger, and H. Lin, The Substrate Specificity of Sirtuins

, Annu Rev Biochem. 2 juin, vol.85, issue.1, pp.405-434, 2016.

P. J. Elliott and M. Jirousek, Sirtuins: Novel targets for metabolic disease

B. Shoba, Z. M. Lwin, L. S. Ling, B. Bay, G. W. Yip et al., Function of Sirtuins in Biological Tissues, Anat Rec Adv Integr Anat Evol Biol. avr, vol.292, issue.4, p.43, 2009.

R. M. Anderson, K. J. Bitterman, J. G. Wood, O. Medvedik, and D. A. Sinclair, Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae, Nature. mai, vol.423, issue.6936, pp.181-186, 2003.

S. J. Lin, P. A. Defossez, and L. Guarente, Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae, Science. 22 sept, vol.289, issue.5487, pp.2126-2134, 2000.

H. Y. Cohen, C. Miller, K. J. Bitterman, N. R. Wall, B. Hekking et al., Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase, Science. 16 juill, vol.305, issue.5682, pp.390-392, 2004.

S. C. Kim, R. Sprung, Y. Chen, Y. Xu, H. Ball et al., Substrate and functional diversity of lysine acetylation revealed by a proteomics survey, Mol Cell. août, vol.23, issue.4, pp.607-625, 2006.

J. Huang, M. D. Hirschey, T. Shimazu, L. Ho, and E. Verdin,

, Biochim Biophys Acta BBA -Proteins Proteomics. août, vol.1804, issue.8, pp.1645-51, 2010.

K. T. Howitz, K. J. Bitterman, H. Y. Cohen, D. W. Lamming, S. Lavu et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan, Nature. sept, vol.425, issue.6954, pp.191-197, 2003.

B. Szczepankiewicz and P. Ng, Sirtuin Modulators: Targets for Metabolic Diseases and Beyond, Curr Top Med Chem, vol.8, issue.17, pp.1533-1577, 2008.

V. M. Nayagam, X. Wang, Y. C. Tan, A. Poulsen, K. C. Goh et al.,

, Modulating Compounds from High-Throughput Screening as Anti-Inflammatory and Insulin-Sensitizing Agents, J Biomol Screen. déc, vol.11, issue.8, pp.959-67, 2006.

C. B. Vu, J. E. Bemis, J. S. Disch, P. Y. Ng, J. J. Nunes et al., Discovery of Imidazo[1,2-b ]thiazole Derivatives as Novel SIRT1 Activators, J Med Chem. 12 mars, vol.52, issue.5, pp.1275-83, 2009.

V. Carafa, D. Rotili, M. Forgione, F. Cuomo, E. Serretiello et al., Sirtuin functions and modulation: from chemistry to the clinic, Clin Epigenetics

, Disponible sur, vol.8, 2016.

J. C. Milne, P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith et al., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes, Nature, vol.450, issue.7170, pp.712-718, 2007.

H. Dai, L. Kustigian, D. Carney, A. Case, T. Considine et al., SIRT1 Activation by Small Molecules, J Biol Chem, vol.22, issue.43, pp.32695-703, 2010.

P. Bieganowski and C. Brenner, Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans, Cell. mai, vol.117, issue.4, p.495, 2004.

D. Sur,

C. Cantó, R. H. Houtkooper, E. Pirinen, D. Y. Youn, M. H. Oosterveer et al.,

, The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet induced obesity, 47. 75. Nicotinamide riboside. In: Wikipedia [Internet, vol.15, p.838, 2012.

D. Sur,

M. Iwabu, T. Yamauchi, M. Okada-iwabu, K. Sato, T. Nakagawa et al., Adiponectin and AdipoR1 regulate PGC-1? and mitochondria by Ca2+ and AMPK/SIRT1, Nature. avr, vol.464, issue.7293, pp.1313-1322, 2010.

L. Otvos, D. Knappe, R. Hoffmann, I. Kovalszky, J. Olah et al., Identification of Adiponectin Receptor Agonist Utilizing a Fluorescence Polarization Based High Throughput Assay. Tasken K, éditeur, PLoS ONE. 14 mai, vol.17, issue.5, p.63354, 2013.

L. Otvos, E. Haspinger, L. Russa, F. Maspero, F. Graziano et al., Design and development of a peptide-based adiponectin receptor agonist for cancer treatment, BMC Biotechnol, vol.11, issue.1, p.90, 2011.

M. Okada-iwabu, T. Yamauchi, M. Iwabu, T. Honma, K. Hamagami et al., A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity, Nature. nov, vol.503, issue.7477, pp.493-502, 2013.

J. Lin, H. Wu, P. T. Tarr, C. Zhang, Z. Wu et al., Transcriptional coactivator PGC-1a drives the formation of slow-twitch muscle fibres, vol.418, p.5, 2002.

D. K. Krämer, M. Ahlsén, J. Norrbom, E. Jansson, N. Hjeltnes et al., Human skeletal muscle fibre type variations correlate with PPAR?, PPAR? and PGC-1? mRNA, Acta Physiol, 2006.

D. Constantin-teodosiu, D. J. Baker, D. Constantin, and P. L. Greenhaff, PPAR? agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction: PPAR? agonism and fuel metabolism in contracting muscle, J Physiol. 1 janv, vol.587, issue.1, pp.231-240, 2009.

J. Liou, S. Lee, D. Ghelani, N. Matijevic-aleksic, and K. K. Wu, Protection of Endothelial Survival by Peroxisome Proliferator-Activated Receptor-?

, Arterioscler Thromb Vasc Biol. juill, vol.26, issue.7, pp.1481-1488, 2006.

R. L. Stephen, M. Gustafsson, M. Jarvis, R. Tatoud, B. R. Marshall et al., Activation of Peroxisome Proliferator-Activated Receptor ? Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines, p.10

C. Gaudel, C. Schwartz, C. Giordano, N. A. Abumrad, and P. A. Grimaldi, Pharmacological activation of PPAR? promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle, Am J Physiol -Endocrinol Metab. août, vol.295, issue.2, pp.297-304, 2008.

S. Müller-brüsselbach, M. Kömhoff, M. Rieck, W. Meissner, and K. Kaddatz,

J. Adamkiewicz, Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR?-deficient mice, EMBO J. 8 août, vol.26, issue.15, pp.3686-98, 2007.

H. Lim, S. Lee, J. Park, K. Lee, H. Choi et al., PPAR? agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle, Atherosclerosis. févr, vol.202, issue.2, pp.446-54, 2009.

G. D. Barish, A. R. Atkins, M. Downes, P. Olson, L. Chong et al.,

, ! PPAR regulates multiple proinflammatory pathways to suppress atherosclerosis, Proc Natl Acad Sci. 18 mars, vol.105, issue.11, pp.4271-4277, 2008.

W. R. Oliver, J. L. Shenk, M. R. Snaith, C. S. Russell, K. D. Plunket et al., Reduced cholesterol absorption upon PPAR? activation coincides with decreased intestinal expression of NPC1L1, Proc Natl Acad Sci. 24 avr, vol.98, issue.9, pp.526-560, 2001.

M. D. Leibowitz, C. Fiévet, N. Hennuyer, J. Peinado-onsurbe, H. Duez et al., Activation of PPAR? alters lipid metabolism in db/db mice, FEBS Lett. 19 mai, vol.473, issue.3, pp.333-339, 2000.

C. Lee, P. Olson, A. Hevener, I. Mehl, L. Chong et al., PPAR regulates glucose metabolism and insulin sensitivity, Proc Natl Acad Sci. 28 févr, vol.103, issue.9, pp.3444-3453, 2006.

W. J. Zuercher, S. Gaillard, L. A. Orband-miller, E. Chao, B. G. Shearer et al., Identification and Structure?Activity Relationship of Phenolic Acyl Hydrazones as Selective Agonists for the Estrogen-Related Orphan Nuclear Receptors ERR? and ERR?, J Med Chem. mai, vol.48, issue.9, pp.3107-3116, 2005.

H. Greschik, J. Wurtz, S. Sanglier, W. Bourguet, A. Van-dorsselaer et al., Structural and Functional Evidence for Ligand-Independent Transcriptional Activation by the Estrogen-Related Receptor 3, Mol Cell. févr, vol.9, issue.2, pp.303-316, 2002.

I. A. Lang, T. S. Galloway, A. Scarlett, W. E. Henley, M. Depledge et al., Association of Urinary Bisphenol A Concentration With Medical Disorders and Laboratory Abnormalities in Adults

S. M. Rangwala, X. Wang, J. A. Calvo, L. Lindsley, Y. Zhang et al.,

, Estrogen-related Receptor ? Is a Key Regulator of Muscle Mitochondrial Activity and Oxidative Capacity, J Biol Chem. 16 juill, vol.285, issue.29, pp.22619-22648, 2010.

K. E. Wellen, G. Hatzivassiliou, U. M. Sachdeva, T. V. Bui, J. R. Cross et al.,

. Atp-citrate, Lyase Links Cellular Metabolism to Histone Acetylation, Science. 22 mai, vol.324, issue.5930, pp.1076-80, 2009.

M. Biel, A. Kretsovali, E. Karatzali, J. Papamatheakis, and A. Giannis, Design, Synthesis, and Biological Evaluation of a Small-Molecule Inhibitor of the Histone Acetyltransferase Gcn5, Angew Chem Int Ed. 26 juill, vol.43, issue.30, pp.3974-3980, 2004.

F. Chimenti, B. Bizzarri, E. Maccioni, D. Secci, A. Bolasco et al., A Novel Histone Acetyltransferase Inhibitor Modulating Gcn5 Network: Cyclopentylidene-[4-(4--chlorophenyl)thiazol-2-yl)hydrazone, J Med Chem. 22 janv, vol.52, issue.2, pp.530-536, 2009.

C. Lee, J. Zeng, B. G. Drew, T. Sallam, A. Martin-montalvo et al., The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance, Cell Metab. mars, vol.21, issue.3, pp.443-54, 2015.

O. Monestier, C. Brun, K. Heu, B. Passet, M. Malhouroux et al., Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype, BMC Genomics, vol.13, issue.1, p.541, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01000773

G. C. Laurentino, C. Ugrinowitsch, H. Roschel, M. S. Aoki, A. G. Soares et al., Strength Training with Blood Flow Restriction Diminishes Myostatin Gene Expression, Med Sci Sports Exerc. mars, vol.44, issue.3, pp.406-418, 2012.

J. J. Hulmi, J. P. Ahtiainen, T. Kaasalainen, P. ??llanen, E. Hakkinen et al., Postexercise Myostatin and Activin IIb mRNA Levels: Effects of Strength Training

!. ,

, Med Sci Sports Exerc. févr, vol.39, issue.2, pp.289-97, 2007.

A. Saremi, R. Gharakhanloo, S. Sharghi, M. R. Gharaati, B. Larijani et al., Effects of oral creatine and resistance training on serum myostatin and GASP-1, Mol Cell Endocrinol. 12 avr, vol.317, issue.1, p.30, 2010.

R. C. Smith and B. K. Lin, Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders: Curr Opin Support Palliat Care, vol.7, p.60, 2013.

M. Saitoh, J. Ishida, N. Ebner, and S. D. Anker, Von Haehling S. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy, JCSM Clin Rep, vol.2, issue.1, 2017.

C. Campbell, H. J. Mcmillan, J. K. Mah, M. Tarnopolsky, K. Selby et al., Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial: Myostatin Inhibitor in DMD, Muscle Nerve. avr, vol.55, issue.4, pp.458-64, 2017.

H. Yamamoto, E. G. Williams, L. Mouchiroud, C. Cantó, W. Fan et al., NCoR1 Is a Conserved Physiological Modulator of Muscle Mass and Oxidative Function, Cell, vol.147, issue.4, p.39, 2011.

M. Thevis and W. Schänzer, Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls, J Pharm Biomed Anal. déc, vol.101, pp.66-83, 2014.

K. Walpurgis, A. Thomas, W. Schänzer, and M. Thevis, Myostatin inhibitors in sports drug testing: Detection of myostatin-neutralizing antibodies in plasma/serum by affinity purification and Western blotting, PROTEOMICS -Clin Appl. févr, vol.10, issue.2, p.205, 2016.

, Four riders each handed two year bans for use of GW501516

, AMA diffuse un message d'alerte au GW501516 (21 Mars, 2013.

. Agence, , 2013.

, Rapport sur les données de contrôle antidopage | Agence mondiale antidopage

D. , intérêt de la Santé publique ma profession avec conscience et de respecter non seulement la législation en vigueur mais aussi les règles de l'Honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine

, De ne dévoiler à personne les secrets qui m'auraient été confiés ou dont j'aurais

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser les actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses

, Que je sois méprisé de mes Confrères si je manque à mes engagements

, Dopage : nouveaux médicaments influant sur la biogenèse mitochondriale et musculaire

. D. Th, . Pharm, and . Rouen, Dans les molécules antagonistes on retrouve les inhibiteurs de l'histone acétyltransférase GCN5 (par exemple MB-3, CPTH2), un inhibiteur du cycle folate-méthionine (MOTS-c), des inhibiteurs des voies de signalisation de la myostatine (par exemple Stamulumab, PINTA-745, REGN-2477, Ramatercept, BMS-986089, Bimagrumab). Le co-répresseur des récepteurs nucléaires 1 (NCoR-1) a été identifié comme une cible potentielle viable dans l'amélioration de la fonction musculaire mais aucun inhibiteur de cette protéine n'a encore été rapporté à ce jour. Certains de ces composés ont déjà fait l'objet d'utilisations abusives par des sportifs dans le but d'améliorer leurs performances. La nécessité de mettre en place des mesures antidopage préventives et proactives semble indispensable à la lutte contre ces nouvelles substances. Cependant le nombre limité d'informations sur leur métabolisme et leur élimination complique fortement les analyses antidopage, MOTS CLES : Dopage -Mitochondries -Muscles striés squelettiques -Sport _______________________________________________________________________________ JURY : Président : Pr Jean Pierre GOULLÉ, Professeur émérite Membres : Pr Michel GUERBET, Professeur Pr Philippe VÉRITÉ, 2019.